DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) was upgraded by analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Thursday, The Fly reports. The brokerage currently has a $7.00 target price on the stock. Oppenheimer’s price target points to a potential upside of 64.71% from the company’s previous […]
Related Keywords
Davidj Wambeke , , Renaissance Technologies , Diamedica Therapeutics Inc , Diamedica Therapeutics Company Profile , Dimensional Fund Advisors , Securities Exchange Commission , Catalyst Financial Partners , Citadel Advisors , Diamedica Therapeutics , Get Rating , Medica Therapeutics , Exchange Commission , Financial Partners , Street Corp , Fund Advisors , Medica Therapeutics Inc , Diamedica Therapeutics Daily , Nasdaq Dmac , Sdmac , Medical , Upgrade , Oppenheimer Holdings Inc ,
vimarsana.com © 2020. All Rights Reserved.